Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or…

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT. JAMA 2022

Document identifier
CEI-BR-095
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT
Title
Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial
Source
JAMA
Year
2022
Volume, issue, pages
327(2):138–150
Digital object identifier
10.1001/jama.2021.23619
PubMed identifier
35015037
Record type
Journal article
Institute identifier
CEI-BR-095

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Monograph: LiraglutideCompound monograph
Trial abstract: STEP-8Trial abstract
Synthesis: Semaglutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Liraglutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Liraglutide in adjunctive therapy in type 1 diabetes: effect on the…Evidence synthesis
Synthesis: Liraglutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Semaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Semaglutide in heart failure with preserved ejection fraction and…Evidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Liraglutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Liraglutide in adjunctive therapy in type 1 diabetes: tolerability…Evidence synthesis
Synthesis: Liraglutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Semaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Semaglutide in heart failure with preserved ejection fraction and…Evidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: Liraglutide in obesity and overweight in adults: durability of effectEvidence synthesis
20 citing documents.

§1.3Subject tags

semaglutide liraglutide head-to-head STEP

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.